Document is current
Any future updates will be listed below
-
Authors
Chivu-Economescu, Mihaela
Herlea, Vlad
Dima, Simona
Sorop, Andrei
Pechianu, Catalin
Procop, Alexandru
Kitahara, Shuji
Necula, Laura
Matei, Lilia
Dragu, Denisa
Neagu, Ana-Iulia
Bleotu, Coralia
Diaconu, Carmen C.
Popescu, Irinel
Duda, Dan G. https://orcid.org/0000-0001-7065-8797
-
Funding
Funding for this research was provided by:
Ministerul Cercetării, Inovării şi Digitalizării (PN-III-P4-ID-PCCF-2016-0158 (contract PCCF 17/2018))
Center for Strategic Scientific Initiatives, National Cancer Institute (R01CA260857, R01CA254351, R01CA247441, R03CA256764, P01CA261669)
Uniformed Services University of the Health Sciences (W81XWH-19-1-0284, W81XWH-21-1-0738)
Japan Society for the Promotion of Science (18K08717)
- License Information
-
More Information
Article History
Received: 5 May 2023
Accepted: 28 August 2023
First Online: 5 September 2023
Declarations
:
: DGD received consultant fees from Innocoll Pharmaceuticals and research grants from Exelixis, Bayer, BMS, and Surface Oncology. No reagents or funding from these companies were used in this study. The other authors declare no conflict of interest.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.
: Informed consent was obtained from all individual participants included in the study.
Free to read: This content has been made available to all.
